The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | Advances in targeted therapies and combination approaches for the treatment of CLL
Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX,
discusses how the treatment landscape for chronic lymphocytic leukemia (CLL) has evolved over the past decade, particularly with the introduction of targeted therapies. He highlights ongoing clinical trials investigating combinations of these therapies and strategies to optimize treatment duration. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
